CompletedPhase 4NCT06027567

The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure

Studying Idiopathic intracranial hypertension

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Rigmor Højland Jensen
Principal Investigator: Rigmor H Jensen, Professor
Danish Headache Center
Intervention: Semaglutide(drug)
Enrollment: 38 enrolled
Eligibility: 18-65 years · FEMALE
Timeline: 2022 – 2025

Study locations (2)

Headache clinic, Department of Neurology, Odense University Hospital, Odense, Odense, Denmark
Danish Headache Center, Department of Neurology, Rigshospitalet, Glostrup Municipality, Denmark

Collaborators

Rigshospitalet, Denmark · Odense University Hospital · University of Copenhagen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06027567 on ClinicalTrials.gov

Other trials for Idiopathic intracranial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic intracranial hypertension →

← Back to all trials